MX9203820A - Ultrapurificacion del factor viii utilizando anticuerpos monoclonales. - Google Patents

Ultrapurificacion del factor viii utilizando anticuerpos monoclonales.

Info

Publication number
MX9203820A
MX9203820A MX9203820A MX9203820A MX9203820A MX 9203820 A MX9203820 A MX 9203820A MX 9203820 A MX9203820 A MX 9203820A MX 9203820 A MX9203820 A MX 9203820A MX 9203820 A MX9203820 A MX 9203820A
Authority
MX
Mexico
Prior art keywords
ultrapurification
monoclonal antibodies
factor viii
viii
factor
Prior art date
Application number
MX9203820A
Other languages
English (en)
Inventor
Theodore S Zimmerman
Carol A Fulcher
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26987116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX9203820(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US06/330,105 external-priority patent/US4361509A/en
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of MX9203820A publication Critical patent/MX9203820A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX9203820A 1981-12-14 1992-06-29 Ultrapurificacion del factor viii utilizando anticuerpos monoclonales. MX9203820A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/330,105 US4361509A (en) 1981-12-14 1981-12-14 Ultrapurification of factor VIII using monoclonal antibodies
US06/563,795 USRE32011E (en) 1981-12-14 1983-12-21 Ultrapurification of factor VIII using monoclonal antibodies

Publications (1)

Publication Number Publication Date
MX9203820A true MX9203820A (es) 1992-07-01

Family

ID=26987116

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9203820A MX9203820A (es) 1981-12-14 1992-06-29 Ultrapurificacion del factor viii utilizando anticuerpos monoclonales.

Country Status (2)

Country Link
US (1) USRE32011E (es)
MX (1) MX9203820A (es)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747337A (en) * 1983-03-31 1998-05-05 The Scripps Research Institute Factor VIII coagulant polypeptides and monoclonal antibodies to them
US5362854A (en) * 1983-03-31 1994-11-08 Scripps Clinic & Research Foundation Factor VIII coagulant polypeptides: method of making
US5004804A (en) * 1984-01-12 1991-04-02 Nordisk Gentofte Method and composition for preparation of factor VIIIC
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US5043428A (en) * 1984-08-31 1991-08-27 Behringwerke Aktiengesellschaft Pasteurized, isoagglutinin-free factor VIII preparation and a process for its production
US5198349A (en) * 1986-01-03 1993-03-30 Genetics Institute, Inc. Method for producing factor VIII:C and analogs
CA1339946C (en) * 1987-03-31 1998-07-07 Michael J. Griffith Ultrapurification process for polypeptides
US5200510A (en) * 1987-06-16 1993-04-06 Zymogenetics, Inc. Method for purifying factor viii:c, von willebrand factor and complexes thereof
US5006642A (en) 1987-06-29 1991-04-09 Rhone-Poulenc Rorer Pharmaceuticals Inc. Purification of von Willebrand Factor by affinity chromatography
US4831118A (en) 1987-08-07 1989-05-16 Scripps Clinic And Research Foundation Flouroplastic immunoaffinity columns for purification of blood proteins
US5605884A (en) * 1987-10-29 1997-02-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Factor VIII formulations in high ionic strength media
US4877608A (en) 1987-11-09 1989-10-31 Rorer Pharmaceutical Corporation Pharmaceutical plasma protein formulations in low ionic strength media
US5888974A (en) * 1992-04-07 1999-03-30 Emory University Hybrid human/animal factor VIII
US5364771A (en) * 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) * 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5663060A (en) * 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5288853A (en) * 1992-04-30 1994-02-22 Alpha Therapeutic Corporation Factor viii purification process
US6248555B1 (en) * 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US6391547B1 (en) 1997-09-09 2002-05-21 Center For The Application Of Molecular Biology To International Agriculture Microbial β-glucuronidase genes, gene products and uses thereof
US7087420B1 (en) 1997-07-17 2006-08-08 Cambia Microbial β-glucuronidase genes, gene products and uses thereof
JP2002516061A (ja) 1997-10-14 2002-06-04 ダーウィン モレキュラー コーポレイション チミジンキナーゼ変異体ならびにチミジンキナーゼ活性およびグアニル酸キナーゼ活性を有する融合タンパク質
CA2340790C (en) * 1998-08-21 2012-07-10 Immunex Corporation Human il-1 epsilon dna and polypeptides
US5994310A (en) 1998-09-03 1999-11-30 Bayer Corporation Peptide ligands for affinity purification of human Factor VIII
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
BRPI9915679B8 (pt) * 1998-11-27 2021-05-25 Darwin Discovery Ltd composições e métodos para aumentar a mineralização óssea
US7063850B1 (en) * 1998-12-22 2006-06-20 University Of Tennessee Research Foundation Protective antigen of group A Streptococci
US6911429B2 (en) 1999-04-01 2005-06-28 Transition Therapeutics Inc. Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US6864235B1 (en) * 1999-04-01 2005-03-08 Eva A. Turley Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
US7507542B2 (en) 2001-05-08 2009-03-24 Ucb Sa Method for regulating immune function using the FOXP3 protein
AU2002365223A1 (en) 2001-10-26 2003-09-02 Id Biomedical Corporation Of Washington Multivalent streptococcal vaccine compositions and methods for use
US20050233321A1 (en) * 2001-12-20 2005-10-20 Hess John W Identification of novel polymorphic sites in the human mglur8 gene and uses thereof
AU2003222568B2 (en) 2002-01-11 2009-05-07 Bioasis Technologies, Inc. Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
AU2003221841A1 (en) 2002-04-03 2003-10-27 Celltech R And D, Inc. Association of polymorphisms in the sost gene region with bone mineral density
RS20050934A (en) * 2003-06-16 2008-04-04 Celltech R. & D. Inc., Antibodies specific for sclerostin and methods fo r increasing bone mineralization
GB0317592D0 (en) 2003-07-26 2003-08-27 Astrazeneca Ab Method
JP2007511738A (ja) 2003-08-08 2007-05-10 ジーンニュース インコーポレーテッド 変形性関節症のバイオマーカー及びその使用
US20060204442A1 (en) * 2003-09-12 2006-09-14 Bankruptcy Estate Of Ferx, Inc. Magnetically targetable particles comprising magnetic components and biocompatible polymers for site-specific delivery of biologically active agents
WO2005111083A2 (en) 2004-04-29 2005-11-24 Otsuka Pharmaceutical Co., Ltd. Antibodies specific for glycoprotein vi and methods of producing these antibodies
JP5265923B2 (ja) 2005-02-07 2013-08-14 ジーンニュース インコーポレーテッド 軽度の変形性関節症のバイオマーカーおよびその使用
ITMI20050739A1 (it) * 2005-04-22 2006-10-23 Effebi Spa Piastrina di connsessione valvola-attuatore
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
ATE518007T1 (de) 2005-10-21 2011-08-15 Genenews Inc Verfahren und vorrichtung zur korrelierung der ebenen von biomarker-produkten mit erkrankungen
AU2007244705A1 (en) * 2006-04-27 2007-11-08 Barnes-Jewish Hospital Detection and imaging of target tissue
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
EP2460828A3 (en) * 2006-11-10 2012-08-08 UCB Pharma, S.A. Antibodies and diagnostics
US20100036091A1 (en) * 2006-11-10 2010-02-11 Amgen Inc. Antibody-based diagnostics and therapeutics
TWI573802B (zh) 2007-03-06 2017-03-11 安美基公司 變異之活動素受體多肽及其用途
WO2013106175A1 (en) 2011-12-19 2013-07-18 Amgen Inc. Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof
US8501678B2 (en) 2007-03-06 2013-08-06 Atara Biotherapeutics, Inc. Variant activin receptor polypeptides and uses thereof
US7982016B2 (en) 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
CL2008002775A1 (es) 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
US20110044978A1 (en) * 2007-12-14 2011-02-24 Amgen Inc. Method for treating bone fracture
EP2361093A2 (en) 2008-11-26 2011-08-31 Five Prime Therapeutics, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
SG171813A1 (en) 2008-11-26 2011-07-28 Amgen Inc Variants of activin iib receptor polypeptides and uses thereof
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
CA2682429A1 (en) * 2009-05-20 2010-11-20 Gary Levy An assay for measuring plasma fgl-2 and methods and uses thereof
AU2010330794A1 (en) 2009-12-18 2012-06-21 Amgen Inc. Wise binding agents and epitopes
DK3195880T3 (da) 2010-05-14 2020-03-02 Amgen Inc Højkoncentrerede anti-sclerostin-antistofformuleringer
MX2013010011A (es) 2011-03-01 2014-10-24 Amgen Inc Agentes de unión biespecífica.
MA35009B1 (fr) 2011-03-25 2014-04-03 Amgen Inc Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
SI2739311T1 (en) 2011-08-04 2018-07-31 Amgen Inc. Method for the treatment of bone defect defects
JP6363954B2 (ja) 2011-12-28 2018-07-25 アムジエン・インコーポレーテツド 抗スクレロスチン抗体の使用による歯槽骨消失の治療方法
EP3626267A1 (en) 2012-07-05 2020-03-25 UCB Pharma, S.A. Treatment for bone diseases
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
CN104620093B (zh) 2012-08-23 2018-04-20 干细胞技术公司 用于快速可逆生物分子标记的组合物和方法
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP2951205B1 (en) 2013-02-01 2021-08-11 Santa Maria Biotherapeutics, Inc. Anti-activin-a compounds for the treatment of ovarian cancer
WO2015071759A1 (en) 2013-11-15 2015-05-21 Institut Pasteur A molecular marker of plasmodium falciparum artemisinin resistance
EP2960252A1 (en) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase for treatment of immunosuppression
JP2017515841A (ja) 2014-05-13 2017-06-15 バヴァリアン・ノルディック・アクティーゼルスカブ 腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法
CA2956385A1 (en) 2014-07-25 2016-01-28 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
EP3285811A1 (en) 2015-04-21 2018-02-28 Institut Gustave Roussy Therapeutic methods, products and compositions inhibiting znf555
WO2017134265A1 (en) 2016-02-05 2017-08-10 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
EP3538553A4 (en) 2016-11-08 2020-11-25 University of Miami ANTI-SECRETOGRANIN III (SCG3) ANTIBODIES AND USES THEREOF
WO2019077165A1 (en) 2017-10-20 2019-04-25 Institut Curie DAP10 / 12-BASED CHIMERIC ANTIGENIC RECEPTORS (CAR) ADAPTED FOR RUSH
EP3530282A1 (en) 2018-02-27 2019-08-28 Diaccurate Therapeutic methods
SG11202008206TA (en) 2018-03-30 2020-09-29 Amgen Inc C-terminal antibody variants
JP7555334B2 (ja) 2018-10-05 2024-09-24 バヴァリアン・ノルディック・アクティーゼルスカブ 組み換えｍｖａ、及び免疫チェックポイントアンタゴニストまたは免疫チェックポイントアゴニストの静脈内投与によって、がんを治療する併用療法
JP2022507744A (ja) 2018-11-20 2022-01-18 バヴァリアン・ノルディック・アクティーゼルスカブ ４－１ｂｂｌ（ｃｄ１３７ｌ）及び／またはｃｄ４０ｌをコードする組み換えｍｖａの腫瘍内及び／または静脈内投与によって、がんを治療する療法
EP3693063A1 (en) 2019-02-06 2020-08-12 Diaccurate Methods and compositions for treating cancer
BR112022009798A2 (pt) 2019-11-20 2022-10-18 Bavarian Nordic As Vírus mva recombinante para administração intratumoral e/ou intravenosa para tratamento de câncer
US11815513B2 (en) 2020-04-01 2023-11-14 Institut Pasteur Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics
US20210311054A1 (en) 2020-04-01 2021-10-07 Institut Pasteur Severe acute respiratory syndrome (sars) - associated coronavirus diagnostics
WO2021209824A1 (en) 2020-04-17 2021-10-21 Institut Pasteur Methods and products for serological analysis of sars-cov-2 infection
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
EP4214223A1 (en) 2020-09-21 2023-07-26 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
WO2023118508A1 (en) 2021-12-23 2023-06-29 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3652530A (en) * 1967-08-28 1972-03-28 American Nat Red Cross Antihemophilic factor prepared from blood plasma using polyethylene glycol
US3631018A (en) * 1970-05-01 1971-12-28 Baxter Laboratories Inc Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate
US3682881A (en) * 1970-10-02 1972-08-08 Baxter Laboratories Inc Fractionation of plasma using glycine and polyethylene glycol
US3973002A (en) * 1974-04-12 1976-08-03 E. R. Squibb & Sons, Inc. Antihemophilic factor
US4188318A (en) * 1975-06-16 1980-02-12 Edward Shanbrom Simplified method for preparation of high yield, high purity Factor VIII concentrate
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
US4137223A (en) * 1977-05-16 1979-01-30 Edward Shanbrom, Inc. Method of preserving blood plasma II
US4296027A (en) * 1977-08-31 1981-10-20 The Regents Of The University Of Minnesota Pure intravenous human and animal gamma globulins
CA1074698A (en) * 1977-12-19 1980-04-01 Gail A. Rock Method of collecting anti-hemophilic factor viii from blood and blood plasma
US4381295A (en) * 1979-04-26 1983-04-26 Ortho Pharmaceutical Corporation Monoclonal antibody to human helper T cells and methods of preparing same
US4272521A (en) * 1979-07-16 1981-06-09 Cutter Laboratories, Inc. Purified immune serum globulin
US4364932A (en) * 1979-09-18 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to human cytotoxic and suppressor T cells and methods of preparing same
US4361550A (en) * 1979-12-04 1982-11-30 Ortho Pharmaceutical Corporation Complement-fixing monoclonal antibody to human suppressor T cells and methods of preparing same
US4364933A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human thymocyte antigen and methods of preparing same
US4364934A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human early thymocyte antigen and methods for preparing same
US4364935A (en) * 1979-12-04 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human prothymocyte antigen and methods of preparing same
SE448945B (sv) * 1979-12-20 1987-03-30 Blombaeck E G B Forfarande for rening och /eller koncentrering av faktor viii-komplexet
US4364937A (en) * 1980-01-08 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human T cell antigen and methods of preparing same
US4364936A (en) * 1980-01-08 1982-12-21 Ortho Pharmaceutical Corporation Monoclonal antibody to a human monocyte antigen and methods of preparing same
NL8000173A (nl) * 1980-01-11 1981-08-03 Akzo Nv Toepassing van in water dispergeerbare, hydrofobe kleurstoffen als label in immunochemische testen.
US4302445A (en) * 1980-01-18 1981-11-24 Institut Merieux Method for concentrating and purifying antihemophilic factor or factor VIII
EP0232921B1 (en) * 1980-04-09 1992-10-07 Btg International Limited Monoclonal antibodies against hepatitis b virus
US4361647A (en) * 1980-05-22 1982-11-30 Palo Alto Medical Research Foundation Sandwich immunoassay and compositions for use therein
US4364861A (en) * 1980-05-27 1982-12-21 Cutter Laboratories, Inc. Blood-coagulation-promoting products and methods of preparing them
US4361510A (en) * 1980-05-27 1982-11-30 Cutter Laboratories, Inc. Blood coagulation promoting product
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4381292A (en) * 1980-11-14 1983-04-26 The Board Of Trustees Of The Leland Stanford Jr. University Anti-human T-lymphocyte monoclonal antibody
US4362867A (en) * 1980-12-10 1982-12-07 Research Corporation Recombinant cDNA construction method and hybrid nucleotides useful in cloning

Also Published As

Publication number Publication date
USRE32011E (en) 1985-10-22

Similar Documents

Publication Publication Date Title
MX9203820A (es) Ultrapurificacion del factor viii utilizando anticuerpos monoclonales.
IT8319234A0 (it) Procedimento per la produzione di anticorpi monoclonali umani.
DE3382572D1 (de) Antikoerper-verbindungen.
ATE34076T1 (de) Shampoo.
NL930118I2 (nl) Ultragezuiverd factor VIII: C preparaat.
IT8222212A0 (it) Dentifricio calciofosfofluorurato.
DE3382283D1 (de) Monoklonale antikoerper spezifisch gegen das karzinoembryonische antigen.
FR2513250B1 (fr) Nouvelles cyclobutene-3,4-diones substituees
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
IT8320550A0 (it) Procedimento di purificazione peraffinita' in cui si impiegano anticorpi monoclonali.
NO159884C (no) Monoklonalt antistoff.
IT8124862A0 (it) Produzione di anticorpi monoclonali umani mediante ibridomi umani.
DE3885355D1 (de) Monoklonale Antikörper.
IT7920592A0 (it) Determinazione di antigeni oppure di anticorpi.
DE3177276D1 (de) Monoklonale antikoerper.
ES527730A0 (es) Anticuerpos monoclonales
DE3280164D1 (de) Numerisches steuerverfahren.
NO873774D0 (no) Monoklonale eller polyklonale antistoffer.
NL176234C (nl) Trilinrichting.
DE3586808D1 (de) L-thyroxin erkennende monoklonale antikoerper.
NO823400L (no) Sadelopplagring.
IT8322114A0 (it) Composti di peptidi sostituiti.
DE3785795D1 (de) Monoklonale anti-menschliche magenkrebs-antikoerper.
FR2500754B1 (fr) Anticorps monoclonaux
NL191578C (nl) Vouwbalg.